ProCE Banner Series

Estrogen Receptor Mutations in HR+ Advanced Breast Cancer: Next-Generation Practice Recommendations on Mutation Screening to Guide Therapeutic Decisions

Live satellite symposium with a panel of experts covering estrogen receptor mutations in HR+ advanced breast cancer, including recommendations on mutation screening to guide therapeutic decision-making with selective estrogen receptor degraders (SERDs).

This symposium is sponsored by Clinical Care Options, LLC and supported by educational grants from AstraZeneca and Lilly. This is not an official program of the San Antonio Breast Cancer Symposium®

  AMA
Who Should Attend

This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

All Events

Estrogen Receptor Mutations in HR+ Advanced Breast Cancer: Next-Generation Practice Recommendations on Mutation Screening to Guide Therapeutic Decisions

Upcoming Events

December

12

2024

7:00 PM - 9:00 PM Central Time (CT)

In-person

Marriott Rivercenter on the River Walk Hotel, 101 Bowie Street, San Antonio, Texas 78205

7:30 PM - 9:00 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

ProCE Banner Faculty
Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

ProCE Banner Faculty
Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and confidence of learners to optimally employ oral SERDs for patients with HR+/HER2- breast cancer. 

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Plan individualized treatment with oral SERDs for patients with HR+/HER2- breast cancer progressing after endocrine therapy based on individual patient and disease characteristics, genomic profile, available clinical data, new approvals, and expert recommendations
  • Describe to patients and colleagues the value of testing for ESR1 mutations and the role of ESR1 in treatment resistance and as a marker of ineffective therapy that should be changed
  • Effectively mitigate and manage toxicities associated with oral SERD therapy for patients with HR+/HER2- breast cancer
  • Identify patients with HR+/HER2- breast cancer who may be eligible for enrollment on clinical trials investigating oral SERDs or other precision medicine approaches

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Lilly.